# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-23-053169
Filing Date
2023-04-28
Accepted
2023-04-28 17:22:13
Documents
5
Period of Report
2023-06-13

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | tm231966-1_def14a.htm | DEF 14A | 728034
2 | GRAPHIC | px_cyclacelproxy2pg01-bw.jpg | GRAPHIC | 666072
3 | GRAPHIC | px_cyclacelproxy2pg02-bw.jpg | GRAPHIC | 598167
4 | GRAPHIC | px_cyclacelproxy2pg03-bw.jpg | GRAPHIC | 525427
5 | GRAPHIC | px_cyclacelproxy2pg04-bw.jpg | GRAPHIC | 495200
| Complete submission text file | 0001104659-23-053169.txt |  | 3400181

Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-50626 | Film No.: 23868421
SIC: 2834 Pharmaceutical Preparations